• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2011 Fiscal Year Research-status Report

HGFプロモーター遺伝子変異によるEGFRチロシンキナーゼ阻害薬の効果予測

Research Project

Project/Area Number 23701106
Research InstitutionKinki University

Principal Investigator

荒尾 徳三  近畿大学, 医学部, 講師 (20441074)

Project Period (FY) 2011-04-28 – 2013-03-31
KeywordsHGF / 肺がん / 遺伝子変異 / SNP / プロモーター
Research Abstract

1年目の本年度は、HGFプロモーターの基礎研究を行った。固形がん細胞73細胞株を対象にHGFプロモーターpoly A領域の変異を検討したところ、Short polyA (< 25bp)の細胞株が7株、正常型のpolyAの細胞株は66株であった。73細胞株のHGFのmRNA発現をrealtime RT-PCRで解析し、HGFのmRNA高値の細胞株では29% (2株/7株)がShort polyAで、HGFのmRNA低値株では3%(2株/66株)であった。予想通りHGFのmRNA高値株は、Short polyAである頻度が有意に高いことが示された (p=0.04)。次にHGFタンパクの分泌量をELISAで検討したところ、Short polyAである H69細胞とIM95細胞が、他株と比べて1000倍以上HGFタンパクを分泌することを見出した。一方、Short polyAでもHGF低値の細胞株が存在したことから、HGFプロモーターのSNPを検討した。SNPは、-2142[C/A, rs11763015], -1965[G/T], -1903[G/A], -1652[C/T, rs3735520], -1268[G/C], -1215[-/C], -955[T/C], -578[T/C], +247[-/T, rs72525097]の9個のSNPを検討した。HGF高値のIM95細胞は、rs3735520がC/Aアレルであったのに対して、他の18株はCアレルであった。rs72525097についてもShort polyA株で頻度が高い傾向を認めた。HGFプロモーターの解析方法としては、自動ゲル解析装置の簡便スクリーニング系およびシークエンスの検証方法を確立した。研究は来年の臨床検体の検討に向けて予定通り順調に進行している。

Current Status of Research Progress
Current Status of Research Progress

2: Research has progressed on the whole more than it was originally planned.

Reason

本年度は、がん細胞株73株を対象にHGF発現とHGFプロモーターのshort polyAおよびSNPの関連を基礎研究で確認した。検出系も確立し、来年度からの臨床検体の解析に向けて順調に進行している。

Strategy for Future Research Activity

次年度からの2年で、(1)肺癌検体でのHGFプロモーターpolyA個数とHGF発現量の相関解析(2) 肺癌検体でのHGF発現量とEGFR-TKIs治療の臨床的相関解析を予定している。

Expenditure Plans for the Next FY Research Funding

本年度と同じように遺伝子変異解析に伴う消耗品に対して使用を計画している。

  • Research Products

    (36 results)

All 2012 2011

All Journal Article (21 results) (of which Peer Reviewed: 21 results) Presentation (14 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells.2012

    • Author(s)
      Aomatsu, K.
    • Journal Title

      Invest Ophthalmol Vis Sci

      Volume: 53(2) Pages: 751-6

    • DOI

      10.1167/iovs.11-8222

    • Peer Reviewed
  • [Journal Article] SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in fastrointestinal cancer.2012

    • Author(s)
      Tanaka, K.
    • Journal Title

      Plos One

      Volume: 7(1) Pages: e27922

    • DOI

      10.1371/journal.pone.0027922

    • Peer Reviewed
  • [Journal Article] FGFR2 gene amplification and clinicopathological featuers in gastric cancer.2012

    • Author(s)
      Matsumoto, K.
    • Journal Title

      Br J Cancer

      Volume: 106(4) Pages: 727-32

    • DOI

      10.1038/bjc.2011.603

    • Peer Reviewed
  • [Journal Article] Plasuma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.2012

    • Author(s)
      Sakamoto, H.
    • Journal Title

      Jpn J Clin Oncol

      Volume: 42(2) Pages: 105-12

    • DOI

      10.1093/jjco/hyr178

    • Peer Reviewed
  • [Journal Article] Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.2012

    • Author(s)
      Furuta, K.
    • Journal Title

      Cancer Sci

      Volume: 103(2) Pages: 221-7

    • DOI

      10.1111/j.1349-7006.2011.02132.x

    • Peer Reviewed
  • [Journal Article] Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.2012

    • Author(s)
      Matsuoka H
    • Journal Title

      Oncol Rep.

      Volume: 27(5) Pages: 1393-9

    • DOI

      10.3892/or.2012.1660

    • Peer Reviewed
  • [Journal Article] Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.2011

    • Author(s)
      Makimura C
    • Journal Title

      Anticancer Res

      Volume: 31(12) Pages: 4561-8.

    • DOI

      10.1007/s00280-011-1738-1

    • Peer Reviewed
  • [Journal Article] What can and cannnot be done using a microarray analysis? Treatment stratification and clinical applications in oncology.2011

    • Author(s)
      Arao T
    • Journal Title

      Biol Pharm Bull

      Volume: 34(12) Pages: 1789-93

    • Peer Reviewed
  • [Journal Article] EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy.2011

    • Author(s)
      Kataoka F
    • Journal Title

      Genes Chromosomes Cancer.

      Volume: 51(3) Pages: 300-12

    • DOI

      10.1002/gcc.21916

    • Peer Reviewed
  • [Journal Article] Serum heparan sulfate concertration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.2011

    • Author(s)
      Nishio M
    • Journal Title

      J Thorac Oncol

      Volume: 6(11) Pages: 1889-94

    • DOI

      ISSN: 1556-0864/11/0611-1889

    • Peer Reviewed
  • [Journal Article] Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.2011

    • Author(s)
      Fujita Y
    • Journal Title

      Invest New Drugs

      Volume: in press Pages: in press

    • DOI

      10.1007/s10637-011-9749-7

    • Peer Reviewed
  • [Journal Article] Activin a inhibits vascular endothelial cell growth and suppresses tumor angiogensis in gastric cancer.2011

    • Author(s)
      Kaneda H
    • Journal Title

      Br J Cancer

      Volume: 5(8) Pages: 1210-7

    • Peer Reviewed
  • [Journal Article] Acquired drug resistanc eto vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular enothelial cells.2011

    • Author(s)
      Arao T
    • Journal Title

      Anticancer Res

      Volume: 31(9) Pages: 2787-96

    • Peer Reviewed
  • [Journal Article] Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells.2011

    • Author(s)
      Okamoto W
    • Journal Title

      Br J Cancer.

      Volume: 105(3) Pages: 407-12.

    • DOI

      10.1038/bjc.2011.246

    • Peer Reviewed
  • [Journal Article] Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.2011

    • Author(s)
      Azuma K
    • Journal Title

      Biochem Biophys Res Commun.

      Volume: 407(1) Pages: 219-24.

    • Peer Reviewed
  • [Journal Article] Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.2011

    • Author(s)
      Nishimura S
    • Journal Title

      Hum Pathol.

      Volume: 42(4) Pages: 516-21.

    • Peer Reviewed
  • [Journal Article] Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.2011

    • Author(s)
      Nagai T
    • Journal Title

      Mol Cancer Ther.

      Volume: 10(1) Pages: 169-77.

    • Peer Reviewed
  • [Journal Article] Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.2011

    • Author(s)
      Kim HK
    • Journal Title

      Pharmacogenomics J.

      Volume: 12(2) Pages: 119-27.

    • DOI

      10.1038/tpj.2010.87

    • Peer Reviewed
  • [Journal Article] TGF-β induces sustained upregulation of SNAI1 and SNAI2 through Smad and non-Smad pathways in a human corneal epithelial cell line.2011

    • Author(s)
      Aomatsu K
    • Journal Title

      Invest Ophthalmol Vis Sci.

      Volume: 52(5) Pages: 2437-43.

    • Peer Reviewed
  • [Journal Article] Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.2011

    • Author(s)
      Kudo K
    • Journal Title

      Clin Cancer Res.

      Volume: 17(6) Pages: 1373-81.

    • Peer Reviewed
  • [Journal Article] Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.2011

    • Author(s)
      Kashiwagi E
    • Journal Title

      Cancer Sci.

      Volume: 102(2) Pages: 382-6.

    • DOI

      10.1111/j.1349-7006.2010.01784.x

    • Peer Reviewed
  • [Presentation] An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma.2011

    • Author(s)
      Nishio, M.
    • Organizer
      American Society of Clinical Oncology Annual Meeting 2011
    • Place of Presentation
      Chicago
    • Year and Date
      2011.6.3-7
  • [Presentation] EMTとバイオマーカー2011

    • Author(s)
      荒尾徳三
    • Organizer
      第15回日本がん分子標的治療学会
    • Place of Presentation
      東京
    • Year and Date
      2011.6.22-24
  • [Presentation] Slug is upregulated during wound healing and downregulates TP63 in corneal epithelial cell.2011

    • Author(s)
      Aomatsu, K.
    • Organizer
      ARVO 2011 Vision Genomics
    • Place of Presentation
      Florida
    • Year and Date
      2011.5.1-5
  • [Presentation] Aza-derivatives of resveratrol are inhibitors of macrophage migration inhibitory factor (MIF).2011

    • Author(s)
      Fujita, Y.
    • Organizer
      American Association for Cancer Research 102nd Annual Meeting 2011
    • Place of Presentation
      Florida
    • Year and Date
      2011.4.2-6
  • [Presentation] Somatic mutation profiling to tumor samples using OncoCarta Panel.2011

    • Author(s)
      Furuta, K.
    • Organizer
      American Association for Cancer Research 102nd Annual Meeting 2011
    • Place of Presentation
      Florida
    • Year and Date
      2011.4.2-6
  • [Presentation] Expression levels of EMT-related genes in hepatocellular carcinoma.2011

    • Author(s)
      Nagai, T.
    • Organizer
      American Association for Cancer Research 102nd Annual Meeting 2011
    • Place of Presentation
      Florida
    • Year and Date
      2011.4.2-6
  • [Presentation] Slug-mediated epithelial mesenchymal transition in lugn cancer cells.2011

    • Author(s)
      Tamura, D.
    • Organizer
      American Association for Cancer Research 102nd Annual Meeting 2011
    • Place of Presentation
      Florida
    • Year and Date
      2011.4.2-6
  • [Presentation] Serum concentrations of angiogenesis-related molecules in patients with pancreatic cancer.2011

    • Author(s)
      Kimura, H.
    • Organizer
      American Association for Cancer Research 102nd Annual Meeting 2011
    • Place of Presentation
      Florida
    • Year and Date
      2011.4.2-6
  • [Presentation] FGFR inhibitor regulates CD133 expression in FGFR2-amplified gastric cancer cells.2011

    • Author(s)
      Matsumoto, K.
    • Organizer
      American Association for Cancer Research 102nd Annual Meeting 2011
    • Place of Presentation
      Florida
    • Year and Date
      2011.4.2-6
  • [Presentation] 血清ヘパラン硫酸濃度とEGRチロシンキナーゼ阻害薬耐性2011

    • Author(s)
      松本和子
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋市
    • Year and Date
      2011.10.3-5
  • [Presentation] 大腸がんにおけるHS6ST2発現とその臨床的特徴2011

    • Author(s)
      木村英晴
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋市
    • Year and Date
      2011.10.3-5
  • [Presentation] 肝細胞癌におけるTJP-1とTwist発現の肝癌切除後の予後への影響2011

    • Author(s)
      永井知行
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋市
    • Year and Date
      2011.10.3-5
  • [Presentation] 非小細胞肺がんにおけるEGFR T790の変異の新規検出法2011

    • Author(s)
      藤田至彦
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋市
    • Year and Date
      2011.10.3-5
  • [Presentation] 胃癌のEMT関連遺伝子発現と化学療法治療予後2011

    • Author(s)
      荒尾徳三
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋市
    • Year and Date
      2011.10.3-5
  • [Patent(Industrial Property Rights)] ソラフェニブの効果予測方法2011

    • Inventor(s)
      荒尾徳三、他
    • Industrial Property Rights Holder
      荒尾徳三、他
    • Industrial Property Number
      特許: 特願2011-104275
    • Filing Date
      2011年05月09日

URL: 

Published: 2013-07-10   Modified: 2013-07-17  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi